知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

732 条记录 (耗时 0.044 秒)

    Compounds for treatment of neurodegenerative diseases
    82.
    发明申请
    Compounds for treatment of neurodegenerative diseases 失效
    用于治疗神经变性疾病的化合物

    公开(公告)号：US20060004041A1

    公开(公告)日：2006-01-05

    申请号：US11120502

    申请日：2005-05-03

    申请人： Christopher Cummings ,  David Lowe ,  William Ripka

    发明人： Christopher Cummings ,  David Lowe ,  William Ripka

    IPC分类号： A61K31/4709 ,  C07D43/02 ,  C07D41/02

    CPC分类号： C07D217/02 ,  A61K31/47 ,  C07D217/06 ,  C07D217/08 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D409/12 ,  C07D417/12 ,  C07D471/04

    摘要： The present invention relates to a class of small molecule hydroxamic acid compounds capable of inhibiting histone deacetylases (HDACs). The present invention also relates to methods of preparation of hydroxamic acid HDAC inhibitor compounds of the invention, which are N-substituted-1,2,3,4-tetrahydroisoquinoline hydroxamic acid derivatives, and their incorporation into pharmaceutical compositions and methods of administration. The present invention also relates to N-substituted-1,2,3,4-tetrahydroisoquinoline hydroxamic acid derivatives, which may be prepared as a hydroxamic acid HDAC inhibitor compound library that can be utilized in screening methods known in the art.

    摘要翻译： 本发明涉及能抑制组蛋白脱乙酰酶（HDAC）的一类小分子异羟肟酸化合物。 本发明还涉及本发明的异羟肟酸HDAC抑制剂化合物的制备方法，它们是N-取代-1,2,3,4-四氢异喹啉异羟肟酸衍生物，以及它们掺入药物组合物和给药方法中。 本发明还涉及可以用于本领域已知的筛选方法中的异羟肟酸HDAC抑制剂化合物文库的N-取代-1,2,3,4-四氢异喹啉异羟肟酸衍生物。

    Novel tetrahydroquinolines
    88.
    发明申请
    Novel tetrahydroquinolines 失效
    新四氢喹啉

    公开(公告)号：US20040254193A1

    公开(公告)日：2004-12-16

    申请号：US10852726

    申请日：2004-05-24

    申请人： Pfizer Inc

    发明人： John Lowe III

    IPC分类号： A61K031/496 ,  C07D43/02

    CPC分类号： C07D217/06

    摘要： The present invention relates to compounds of formula I 1 wherein X and Y are as defined in the specification, and to pharmaceutical compositions comprising the compound of formula I and a pharmaceutically effective carrier; and to a method useful in treating or preventing in mammals, including humans, a disorder or condition selected from the group consisting of anxiety, depression, dysthymia, major depressive disorder, migraine, post-traumatic stress disorder, avoidant personality disorder, borderline personality disorder and phobias.

    摘要翻译： 本发明涉及式I化合物，其中X和Y如说明书中所定义，以及包含式I化合物和药学上有效载体的药物组合物; 以及可用于治疗或预防哺乳动物（包括人），选自焦虑，抑郁，精神抑郁，重度抑郁障碍，偏头痛，创伤后应激障碍，避孕人格障碍，边缘人格障碍 和恐惧症。